Biodel Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s new drug application seeking approval to market VIAject(R) for the treatment of diabetes. VIAject(R) is Biodel’s proprietary formulation of recombinant human insulin that is designed...

Diabetes UK reported today that scientists in Cambridge have shown that an ‘artificial pancreas’ can be used to regulate blood glucose in children with type 1 diabetes. A JDRF funded study found that combining a real-time sensor measuring glucose levels with a pump that delivers insulin can boost overnight blood glucose control.The...

Business Wire reports that Calibra Medical Inc., formerly known as Seattle Medical Technologies Inc., announced today that the U.S. Food and Drug Administration has given Finesse, the company’s insulin patch-pen, 510(k) clearance. Only 2” long, 1” wide and ¼” thick, Finesse is able to hold and deliver prescribed...

Reuters reports on a new review comparing the the use of insulin pumps to insulin shots.  According to the report, the pump is more effective in the treatment of type 1 diabetes. The researchers at the Australasian Cochrane Center at Monash University in Clayton, Australia, identified 23 studies in which a total of 976 people with type...

The Juvenile Diabetes Research Foundation announced it had teamed up Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease – the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial...

MannKind Corp. announced that it was informed today by the Food and Drug Administration that they will not be able to complete the review of MannKind’s new drug application for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.The FDA explained that it has not yet completed its inspection of the insulin...

Biodel, Inc. announced that it has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for clearance to market of VIAject(R) as a treatment for diabetes. VIAjecta(R) is a formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin...

Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications. However, these studies were unable to control for important factors such as obesity that may...

According to a report in SmartPlanet.com insulin injections may soon be replaced by tiny capsules.  Professor of bioengineering at UCSF, Tejal Desai, has developed a capsule which contains millions of pancreatic cells that secrete insulin. This capsule could be implanted into the body, creating an artificial pancreas. When blood sugar...

Eli Lilly and Company announced the availability of a smaller vial of insulin containing 3 mL (300 units), the first such vial in the United States.  A typical vial of insulin contains 10 mL, or 1,000 “units” of insulin. Lilly developed this new smaller vial for use in hospitals based on feedback regarding the average duration...